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Busulphan is an alkylating agent widely used in high-dose
combined chemotherapy regimens before allogeneic or autologous
bone marrow stem cells transplantation. Busulphan is cytotoxic to
quiescent cells, especially to bone marrow stem cells (Dunn 1974).
High-dose busulphan is used either as an alternative to total body
irradiation, particularly in children undergoing allogeneic bone
marrow transplantation for genetic diseases, or as an anti-cancer
drug against haematological diseases such as acute and chronic
myeloid leukaemias.
For a long time, busulphan was considered inactive in malignant
solid tumours, as shown in the early clinical studies conducted
in the late 1960s with long-lasting administration schedules
(Sullivan, 1958; Arduino et al, 1967). However, the specific
cellular target of busulphan, i.e. non-dividing cells, made this drug
particularly attractive for the treatment of solid tumours because of
its potential capacity to kill quiescent tumour cells while residual
disease is minimal. Based on this hypothesis, we designed several
high-dose busulphan-containing regimens in combination with
other alkylating agents, i.e. cyclophosphamide, melphalan or
thiotepa, for the treatment of paediatric malignant solid tumours.
The clinical phase II evaluation of these combined regimens in
relapsed or refractory diseases indicated that high response rates
could be achieved in neuroblastomas (Hartmann et al, 1986) and
Ewing’s sarcomas and medulloblastomas (Kalifa et al, 1992;
Dupuis-Girod et al, 1996). In addition, the use of a high-dose
busulphan containing regimen was shown to be a strong
favourable prognostic factor in terms of disease-free survival in
patients with metastatic neuroblastoma (Hartmann et al, 1997) and
Ewing’s sarcoma (Ladenstein et al, 1997).
However, an important question remains unanswered: is
busulphan active as a single agent against paediatric solid
tumours? Because tumour xenografts are good preclinical models
to evaluate the therapeutic activity of anti-cancer drugs (Mattern et
al, 1988), we addressed this issue by studying busulphan thera-
peutic activity against paediatric malignant tumour xenografts,
along with busulphan pharmacokinetics in nude mice.
MATERIALS AND METHODS
Drug
Busulphan was purchased from Sigma (France). Busulphan
crystals were first dissolved in acetone, and a fine white powder
was obtained after spontaneous evaporation.
Animals
Female SPF-Swiss athymic mice were bred in the Animal
Experimentation Unit, at the Institut Gustave-Roussy (Villejuif,
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Desmoulins, 94805 Villejuif cedex, FranceFrance). The strain was obtained from Carl Hansen (NIH,
Bethesda, MD, USA) in 1976. Animals were housed in sterile
isolators, and fed with irradiated nutriments (UAR,  V illemoisson,
Orge, France) and filtered water ad libitum. Experiments were
carried out under the conditions established by the European
Community (directive no. 86/609/CEE).
Xenografts
The panel comprised one peripheral primitive neuroectodermal
tumour (PNET) exhibiting the EWS-FLI fusion transcript
(SKNMC), three neuroblastomas (IGRN835, IGRNB3, IGRNB8)
and three medulloblastomas (IGRM21, IGRM33, IGRM34).
These xenografts were derived either from established in vitro cell
lines (SKNMC, IGRN835) or from primary tumours by subcuta-
neous transplantation of small fragments in previously irradiated
athymic mice ( V assal et al, 1996  a). The SKNMC cell line was
purchased from the American T ype Culture Collection. The
IGRN835 cell line was established in vitro by J Bénard from a
previously treated stage IV neuroblastoma (Bettan-Renaud et al,
1989). IGRNB3 and IGRNB8 xenografts were established from
newly diagnosed stage III neuroblastomas. These three xenografts
exhibit several molecular and cytogenetic markers of poor prog-
nosis neuroblastoma in children (V assal et al, 1996  b). IGRM21
was derived from a newly diagnosed undi fferentiated medullo-
blastoma, and IGRM33 from a recurrent medulloblastoma after
conventional chemotherapy and radiotherap y. IGRM34 was
derived from a metastatic PNET of the posterior fossa in a 1.6-
year-old bo y, and exhibited the histological features of a PNET
with a rhabdoid phenotype. These three medulloblastoma
xenografts have been previously described and characterized
( V assal et al, 1996  a, 1997). The human origin of the xenografts
was confirmed by the presence of human lactate dehydrogenase
(LDH) isoenzymes and by cytogenetic analysis.
All the xenografts were maintained in vivo by sequential
passaging from s.c. implants, with an engraftment success rate
exceeding 75%. The stability of the xenografts was checked at
each passage by analysing the doubling time, and every 3–6
passages by histological analysis. Drug treatment experiments
were carried out between passages 6 and 17.
Drug formulation and pharmacokinetics
T o evaluate the optimal vehicle and route for the in vivo adminis-
tration of busulphan, plasma pharmacokinetics and toxicity were
first evaluated after oral, intraperitoneal and intravenous adminis-
tration of busulphan in different preparations: a solution in DMSO
(Sigma), a suspension in 2.5% carboxymethylcellulose (CMC)
(Aldrich, France) in wate r, or a suspension in a mixture of CMC
and DMSO. For this last preparation, busulphan was first
dissolved in DMSO (2 4 mg in 0. 4 ml) and then suspended in 2.5%
CMC in wate r.
For the pharmacokinetic analysis, tumou r-free animals aged 7–8
weeks received a single dose of 4 0 mg kg –1 prepared in one of the
different vehicles via one of the three routes of administration. Three
animals were sacrificed by carbon dioxide inhalation before and after
the administration at each of the following time points: 15, 3 0 min, 1,
2, 3, 5 and  7 h. A total blood sample ( 1 ml) was immediately
collected by cardiac puncture in a heparinized vial and plasma was
separated by centrifugation. At each time point, plasma samples from
the three animals were pooled and frozen at –80  °C until analysis.
Plasma busulphan levels were measured by gas chromatography
mass spectrometry, using a tetradeuterated internal standard as
previously described ( V assal et al, 1988).
Model-independent pharmacokinetic analysis was performed
using the W inNonlin program (Scientific Consulting, Car y, NC,
USA). The decrease in the concentration–time curve was monoex-
ponential. Elimination half-lives were determined by linear regres-
sion from the linear portion of the log curve. The areas under the
curve (AUC) were calculated using the linear/log trapezoidal rule
from 0 to  7 h, and extrapolated to infinity according to the elimi-
nation half-life. The total plasma clearance rates (CI) were calcu-
lated by dividing the dose by the AUC. The apparent volumes of
distribution ( Vd) were calculated by dividing the clearance rate by
the slope of the linear portion of the log curve. For each route and
vehicle, the relative bioavailability ( F) was calculated by dividing
the observed AUC by the AUC of the reference dosage, which
proved to be i.p administration in DMSO.
The toxicity of each route and vehicle evaluated was studied in
tumour-bearing animals at doses from 37 to 20 0 mg kg –1, and
expressed as the dose that killed 50% of the treated animals (LD50).
Experimental design
Drug activity against bilateral advanced stage tumours was
evaluated as previously described ( V assal et al, 1996  b). For each
experiment, tumour fragments (1 5 mm 3) were xenotransplanted
subcutaneously in 30–50 athymic mice aged 6–8 weeks. On day 0
of the treatment, mice bearing a 100–40 0 mm 3 subcutaneous
tumour were pooled and randomly assigned to 2–4 groups of 6–9
animals, including one control and 1–3 treated groups.  T wo
tumour perpendicular diameters were measured three times
weekly with a caliper by the same investigato r. Each tumour
volume was calculated according to the following equation:
V(mm3)  =  d2 (mm2) ´D(mm)/2, wher e  dand Dare the smallest
and largest perpendicular tumour diameters respectivel y. Each
group of mice was treated according to the average weight of the
group. Animal body weights were recorded three times weekl y.
Mortality was checked daily and an autopsy was performed when
appropriate. Body weight loss (BWL) was reported as the
maximum treatment-related body weight loss. The experiments
lasted until tumour volumes reached 1500–200 0 mm 3.
Treatment
The objective was to evaluate busulphan anti-tumour activity at
the maximum tolerated dose. Thus, two dose levels, including one
toxic dose level, were used during each experiment. Busulphan in
DMSO was administered i.p. at a dose of 25 and 31.2 5 mg kg –1
(0. 1 ml per animal) on days 0 and 4 for the evaluation of anti-
tumour activity.
Evaluation of anti-tumour activity
Busulphan therapeutic activity was evaluated according to two
criteria: (i) the number of complete and partial tumour regressions;
(ii) the tumour growth delay (TGD). The total tumour burden in each
animal bearing bilateral tumours was considered for the evaluation
of tumour regression. Complete regression (CR) was defined as a
tumour regression beyond the palpable limit (1 5 mm 3), and partial
regression (PR) as a tumour regression greater than 50% of the initial
tumour volume. CR and PR had to be observed for at least two
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was defined as the difference between the treated group and the
control group in the median time to reach a tumour volume that was
five times greater than the initial tumour volume (Vassal, 1996b).
Statistical analysis
For each experiment, the times for each tumour to attain a volume
five times greater than the initial tumour volume in the treated and
control groups were compared using a two-sided non-parametric
Mann–Whitney test.
RESULTS
Optimal drug formulation and route of administration
Because busulphan is highly hydrophobic, we first investigated the
use of several vehicles for enteral and parenteral administration, in
terms of pharmacokinetics and toxicity (Table 1). After a single
administration of 40 mg kg–1, the highest AUC was obtained with
busulphan in DMSO administered i.p., and this was considered the
reference preparation and route. When busulphan was suspended
in carboxymethylcellulose, bioavailability (F) was poor after i.p.
injection (F = 31%), and even poorer when given orally (F = 5%)
(Figure 1A). With the latter formulation, the LD50 could not be
established. When busulphan was administered in a DMSO/CMC
mixture, bioavailability was improved, up to 59%, and the LD50
was 125 mg kg–1. When busulphan was administered in DMSO,
equivalent LD50s, i.e. 60–65 mg kg–1, were observed after i.p. and
i.v. injection. Nevertheless, the bioavailability of the i.v. form was
86% compared with that of the i.p. injection (Figure 1B). This
unexpected result was confirmed in a second separate experiment
(Table 1). This difference was attributed to the venous toxicity of
the formulation which induced leakages. In addition, local cuta-
neous tolerance after a single i.v. administration was poor. The i.p.
administration of busulphan in DMSO was thus considered the
optimal route and preparation in terms of bioavailability and local
tolerance.
Toxicity
During the seven therapeutic experiments, busulphan was given
i.p. in DMSO on day 0 and day 4, at two total dose levels, i.e. 50
and 62.5 mg kg–1. Overall, treatment-related deaths occurred in 4
out of 52 animals (7.6%) and 25 out of 52 animals (48%) at the 50
and 62.5 mg kg–1 dose levels respectively. The dose of 50 mg kg–1
was thus considered as the maximum tolerated dose. Treatment-
related deaths were delayed, with a median day of onset on day 21
(range 15–24). The early body weight loss was not predictive
of treatment-related death. The delayed treatment-related death
allowed the evaluation of tumour regression at dose levels above
the maximum tolerated dose. This is of interest when studying a
compound which is used in the clinical setting at high doses with
bone marrow stem cell rescue. Diffuse purpura and anaemia were
the clinical manifestations of busulphan-induced toxicity. At
higher dose levels, diarrhoea was also observed.
Anti-tumour activity
At the maximum tolerated total dose of 50 mg kg–1, busulphan
induced a significant tumour growth delay ranging from 12 to 34
days in the three neuroblastoma xenografts evaluated (Table 2).
IGRNB3 was the most sensitive, with two of seven animals
showing partial regression of their total tumour burden. Complete
and partial regressions were observed at a higher toxic dose in the
other two neuroblastomas, IGRN835 and IGRNB8. Busulphan
was significantly active in one of three medulloblastoma
xenografts. Indeed, one complete regression with a tumour growth
Busulphan against medulloblastoma and neuroblastoma 789
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Table 1 Plasma pharmacokinetics of busulphan (40 mg kg–1) in athymic mice using different vehicles and routes of administration
Vehicle Route Cmax T1/2 AUC0–∞ F Cl Vd
(mg ml–1) (h) (mg h ml–1) (ml h–1) (ml)
CMC p.o. 2.8 NA 4.4 0.05 228 NA
CMC i.p. 11.1 NA 28.9 0.31 34 NA
CMC/DMSO i.p. 33 0.86 54.3 0.59 18 22.5
DMSO i.p. 44.8 1.16 92.2 1 9.3 15.4
DMSO i.v. 26.3 1.30 80 0.86 11 26
DMSO i.v. 26.9 1.40 75.6 0.82 11.7 23.9
CMC, carboxymethylcellulose; DMSO, dimethylsulphoxide; p.o., per os; i.p., intraperitoneal; Cmax, maximum plasma concentration; T1/2, elimination half-life;
AUC0–∞, area under the curve extrapolated to infinity; F, bioavailability; Cl, clearance rate; Vd, volume of distribution; LD50, dose that kills 50% of animals; NA, not
available. Pharmacokinetics after i.v. administration were evaluated in two separate experiments.
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Figure 1 Busulphan plasma disposition in athymic mice. CMC,
carboxymethylcellulose; DMSO, dimethylsulphoxide; p.o., per os; i.p.,
intraperitonealdelay of 33 days was observed in IGRM21 at the 50 mg kg–1 total
dose level (Figure 2). At a higher dose level, five out of six partial
regressions of the total tumour burden were observed in IGRM21-
bearing animals, with a significant tumour growth delay of 65
days. No therapeutic activity was observed in the last two
medulloblastoma and the peripheral PNET xenografts. Busulphan
proved to be active in four out of seven paediatric solid tumour
xenografts, and a dose–effect relationship was suggested by
tumour regressions observed at dose levels above the maximum
tolerated dose.
DISCUSSION
Busulphan is an old drug, whose clinical development began in the
early 1950s. The preclinical evaluation of its anti-tumour activity
was limited until the recent development of structurally related
compounds, such as hepsulfam (Berger et al, 1992). Busulphan
has, however, been widely used for in vivo preclinical studies on
haematopoiesis and allogeneic bone marrow transplantation
(Josvasen et al, 1973; Tutschka et al, 1977).
Busulphan is poorly soluble in water. Until recently, only an
oral form was available for the administration of conventional and
high doses in humans. Several vehicles have, however, been
reported for enteral and parenteral administration in animals,
including corn oil (Josvasen et al, 1973; Millar et al, 1975), peanut
oil (MacCracken et al, 1988), carboxymethylcellulose (Tutschka
et al, 1977), DMSO (Smalowski et al, 1989), acetone and water
(Bhoopalam et al, 1985; Down et al, 1989), and mixtures of these
different vehicles. Aaron et al (1994) used a single i.p. injection
of busulphan in 10% DMSO in saline and found a DL10 of
60.3 mg m–2 in athymic BALB/c mice bearing CNS tumour
xenografts. Berger et al (1992) reported the use of i.p. administra-
tion of busulphan in pure DMSO in NMRI athymic mice, deliv-
ering an optimal dose of 150 mg kg–1 in a single i.p. injection. We
showed that the bioavailability and toxicity of busulphan was
highly dependent on the vehicle and route of administration. When
pharmacokinetics and local tolerance were considered, intraperi-
toneal administration of busulphan in DMSO was clearly the
optimal route and formulation for in vivo preclinical studies.
These pharmacological results might be of interest for the conduct
of other in vivo preclinical studies, such as those evaluating gene-
modified stem cell transplantation (Yeager et al, 1991). A new
drug formulation in dimethylacetate and polyethyleneglycol has
recently been developed for parenteral administration of busul-
phan in humans (Bhagwatwar et al, 1996).
The preclinical evaluation of the in vivo anti-tumour activity of
busulphan has so far been limited in malignant solid tumour
models. While comparing hepsulfam to busulphan, Berger et al
(1992) showed that busulphan induced tumour growth delays
without tumour regressions in two subcutaneous human tumour
xenografts in athymic mice (stomach and lung carcinomas), and
was inactive in a human melanoma xenograft. In addition, when
busulphan activity was investigated in vitro against a panel of
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Table 2 Anti-tumour activity of i.p. busulphan in athymic mice bearing advanced stage subcutaneous paediatric solid tumour xenografts
Xenograft DT Daily dose Total dose n BWL Toxic CR PR TGD P-value
(histology) (day) (mg kg–1) (mg kg–1) (%) death (day)
IGRN835 4.5 25 50 7 2 0 0 0 12 <0.01
(NB) 31.25 62.5 8 0.5 3 1 2 NE
IGRNB8 4 25 50 7 0 0 0 0 13 <0.0001
(NB) 31.25 62.5 7 7 6 0 2 NE
IGRNB3 7 25 50 8 0 1 0 2 34 <0.0001
(NB) 31.25 62.5 8 0 6 0 1 NE
IGRM21 9 25 50 6 1 0 1 0 33 <0.0001
(MB) 31.25 62.5 6 5 1 0 5 65 <0.0001
IGRM33 15 25 50 8 0 1 0 0 0 NS
(MB) 31.25 62.5 8 0 4 0 0 NE
IGRM34 3 25 50 7 5 1 0 0 6 NS
(MB) 31.25 62.5 7 5 3 0 0 NE
SKNMC 6 25 50 9 0 1 0 0 7 NS
(pPNET) 31.25 62.5 9 0 2 0 0 NE
DT, tumour doubling time; BWL, maximum body weight loss; CR, complete regression; PR, partial regression; TGD, tumour growth delay; NB, neuroblastoma;
MB, medulloblastoma; pPNET, peripheral primitive neuroectodermal tumour; NA, not evaluable. For each experiment, the times of each tumour to attain a
volume five times greater than the initial tumour volume in the treated and control groups were compared using a two-sided non-parametric Mann–Whitney test.
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Figure 2 Anti-tumour activity of busulphan against a medulloblastoma
xenograft (IGRM21). Busulphan was given i.p. in DMSO at a dose of
25 mg kg–1 (s) and 31 mg kg–1 (l) on days 0 and 4. Animals in the control
group (n n) received i.p. DMSO. Each line represents the evolution of the
mean tumour volume in each groupdifferent malignant solid tumour cell lines, busulphan was cyto-
toxic at the highest concentration of 10 mg ml–1 in 12 out of 37 cell
lines (32%), including gastric, lung, breast and testicular cancers
and melanoma. Aaron et al (1994) addressed the issue of busul-
phan anti-tumour activity in brain tumour xenografts in athymic
mice. Busulphan induced a significant tumour growth delay in one
medulloblastoma, two ependymomas and four out of five high-
grade gliomas subcutaneous xenografts evaluated at an advanced
stage. In addition, busulphan increased the median survival of
animals bearing intracranial brain tumour xenografts. Our study
showed that busulphan displayed significant anti-tumour activity
in vivo in three out of three advanced stage subcutaneous neuro-
blastoma xenografts, and in one of three medulloblastoma
xenografts. This activity was dose dependent, as shown by the
increased number of complete and partial regressions above the
maximum tolerated dose. For a long time, busulphan cytotoxicity
was considered to be restricted to haematological malignancies,
and especially myeloid leukaemias. Altogether, these preclinical
data demonstrate that single-agent busulphan displays anti-tumour
activity against malignant solid tumours of various histological
types and even complete regression of some of these tumours.
High-dose busulphan-containing regimens are currently being
investigated for the treatment of advanced and metastatic breast
carcinomas (Demirer et al, 1996).
For the first time, we report the significant in vivo anti-tumour
activity of busulphan against three of three neuroblastoma
xenografts exhibiting molecular markers of poor prognosis in
children. Metastatic neuroblastoma is a frequent malignant solid
tumour in children. Intensified chemotherapy with high-dose
regimens and bone marrow stem cell support have succeeded in
increasing the response rate in refractory or relapsed metastatic
neuroblastomas. During the last 15 years, we have developed high-
dose busulphan-containing regimens for the treatment of metastatic
neuroblastoma (Hartmann et al, 1986). Recently, in a multivariate
retrospective analysis of 218 patients over 1 year of age treated in a
single centre with high-dose chemotherapy and haematopoietic
stem cell transplantation, we showed that the presence of the
busulphan–melphalan combination in the regimen was a strong
independent favourable prognostic factor (Hartmann et al, 1997).
From a pharmacological point of view, busulphan is a very attrac-
tive drug for the treatment of central nervous system malignant
diseases. After oral administration, it is widely distributed in the
cerebrospinal fluid (CSF) with a mean CSF to plasma ratio of 1
(Vassal et al, 1990). Hassan et al (1992) studied brain tissue distrib-
ution of [11C]busulphan using positron-emission tomography scans
in non-human primates and humans (Hassan et al, 1992). This study
showed that 20% of the drug was rapidly and homogeneously
distributed throughout the brain tissue and mainly in the white
matter. Our preclinical study showed that busulphan was very active
in one of three medulloblastoma xenografts. These results along
with those reported by Aaron et al (1994) in several different brain
tumour xenografts suggest that busulphan may be an important drug
worth considering for the treatment of brain tumours in children.
Using a busulphan–thiotepa regimen, we have already reported
a 40–75% response rate in children with relapsed or refractory
medulloblastoma (Kalifa et al, 1992; Dupuis-Girod et al, 1996).
Finally, the pharmacokinetic study performed to determine of
the optimal vehicle and route of administration for busulphan in
animals allowed us to compare the busulphan disposition in nude
mice and humans. The elimination half-life was shorter in mice
(0.86–1.4 h) than in humans (2–3 h). The total plasma clearance
rate was 9.3 ml h–1 in mice receiving a single i.p. administration of
40 mg kg–1. Assuming linear pharmacokinetics, the systemic expo-
sure obtained in mice at the maximum tolerated total dose, i.e.
50 mg kg–1, was expected to be 113 mg h ml–1. We have developed
a new oral dosage for children, i.e. 600 mg m–2, which is able to
eliminate the effect of age on busulphan plasma clearance in chil-
dren (Vassal et al, 1992). In this regimen, busulphan is given orally
at a dose of 37.5 mg m–2 every 6 h for 16 consecutive doses. The
mean systemic exposure after the first dose of this regimen was
6.4 mg h ml–1 in 25 children aged 2–14 years. It can be extrapolated
that the mean total systemic exposure during the 4-day treatment
would be 102.4 mg h ml–1, regardless of the already described
nychthemeral variations (Vassal et al, 1993). The therapeutic effi-
cacy of busulphan in paediatric solid tumour xenografts in nude
mice was therefore observed at total systemic exposure levels that
can be regularly achieved in children receiving high-dose busul-
phan in combined chemotherapy regimens before autologous
haematopoietic stem cell transplantation.
In conclusion, busulphan is an active alkylating agent against
paediatric solid tumour xenografts at plasma levels that can be
achieved clinically in children receiving a high-dose busulphan-
containing regimen. These preclinical results suggest that busul-
phan may be an active drug when used at high dose in combination
with another alkylating agent in childhood solid tumours, and
especially in neuroblastoma and medulloblastoma at a stage of
minimal residual disease.
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